期刊档案 · 医学-病毒学
ANTIVIRAL RESEARCH
ISSN 0166-3542 · eISSN 1872-9096 · Elsevier · NETHERLANDS · Monthly · 创刊 1981
ANTIVIRAL RESEARCH 中科院 医学 2区（2025 年升级版），影响因子 4.22，混合开放获取，APC 约 4,160 美元，投稿社区反馈审稿约 3 个月，录用比例约25%（社区反馈），2025 年发文 183 篇，SCIE、Scopus 收录。
研究范围
研究范围与定位
Antiviral Research aims to publish manuscripts in the field of prevention and treatment of viral diseases in humans and vertebrate animals, and encourages authors to the submit manuscripts describing the activity of well-defined chemical compounds for the treatment of viral diseases. The journal is an Official Publication of the International Society for Antiviral Research. The types of papers published in Antiviral Research includes original research reports, short communications, commentaries and invited review* articles on the control of viral infections in humans. The journal’s scope encompasses:antiviral drugs, antibodies and host-response modifiers, including their synthesis, in vitro and in vivo testing and mechanisms of action.identification and validation of new drug targets;laboratory animal models of viral diseases for antiviral efficacy testing;evolution of drug-resistant viruses and the development of effective counter measures;pathogenesis of viral diseases and mechanisms of viral evasion of host immune responses;assessments of drug safety;new or improved vaccines against viral infections of humans; the prevention and treatment of viral diseases of vertebrate animals, and reports of the testing of veterinary vaccines in the target animal species. All papers must include a sufficiently detailed description of methods to permit other investigators to replicate the experiments. Authors reporting the antiviral effect of a novel small-molecule drug must reveal its chemical structure. Claims of in vitro or in vivo efficacy of a drug or vaccine must be supported by appropriate statistical analysis that must be clearly described in the manuscript.Antiviral Research journal does not publish reports on viral diseases of plants or of insects, crustaceans or other invertebrates. Studies of viral diseases of livestock and companion animals must be clearly related to the development of realistic therapies. Papers on veterinary vaccines should report findings in the target animal species.We discourage the submission of manuscripts reporting the antiviral activity of unpurified natural products, or of partially purified substances of natural origin for which a mechanism of action has not been determined. Manuscripts claiming an antiviral effect of homeopathic products or other highly diluted preparations, or which fail to clearly identify the biological ingredient or molecule responsible for the antiviral activity of an experimental therapy, will not be considered for publication. Articles describing antiseptics with broad-spectrum antimicrobial activity will not be accepted. We discourage the submission of in silico docking studies or other computer-based predictions of antiviral activity that are not supported by data from biological assays. Citations of reports that have not undergone peer review must include the note "[not peer-reviewed]."ISAR members Authors who are ISAR members are encouraged to contact ISAR after their paper has been accepted for publication in order to benefit from their published work being highlighted in ISAR postings on their social media platforms (further details on this will be given in the AVR acceptance letter). *Antiviral Research journal has started a new initiative to publish at least two thematic special issues per year, containing invited reviews in addition to the ad hoc invitations to experts in the areas within the scope of the journal.
摘自期刊官网 Aims & Scope
研究方向（LetPub）：医学-病毒学
主要研究主题 OpenAlex 近年发文统计，占比为近似值
- Herpesvirus Infections and TreatmentsMedicine8.9%
- HIV/AIDS drug development and treatmentMedicine8.6%
- HIV Research and TreatmentImmunology and Microbiology8.2%
- Cytomegalovirus and herpesvirus researchMedicine7.4%
- Hepatitis C virus researchMedicine6.1%
- Hepatitis B Virus StudiesMedicine5.5%
- Virus-based gene therapy researchBiochemistry, Genetics and Molecular Biology4.9%
- Influenza Virus Research StudiesMedicine4.8%
分区与收录
学科分区与数据库收录
中科院期刊分区表
期刊分区表（ 2025年3月升级版）医学 2 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 2 区 |
| 小类 | 药学PHARMACOLOGY & PHARMACY | 2 区 |
| 小类 | 病毒学VIROLOGY | 2 区 |
Top 期刊：否综述期刊：否
《新锐期刊分区表》（ 2026年3月发布）医学 2 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 2 区 |
| 小类 | 药学PHARMACOLOGY & PHARMACY | 2 区 |
| 小类 | 病毒学VIROLOGY | 2 区 |
Top 期刊：否综述期刊：未标注
期刊分区表（ 2023年12月旧的升级版）医学 2 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 2 区 |
| 小类 | 药学PHARMACOLOGY & PHARMACY | 2 区 |
| 小类 | 病毒学VIROLOGY | 2 区 |
Top 期刊：否综述期刊：否
数据库收录
SCIEScopusLetPub
国际期刊预警名单：各版本均未列入LetPub
不同版本、大类与小类分别展示，不将不同评价口径合并为一个分区值；投稿与考核前请确认所在机构采用的版本。
指标
影响力指标与发文规模
影响力指标
- 影响因子
- 4.22LetPub ·
- 影响因子（出版商公布）
- 4.3出版商官网 ·
- CiteScore 2026-06
- 7.8LetPub ·
- CiteScore（出版商公布）
- 7.8出版商官网 ·
- SJR 2026-06
- 1.35LetPub ·
- SNIP 2026-06
- 0.94LetPub ·
- h-index
- 108LetPub ·
- h-index
- 179OpenAlex ·
- i10-index
- 4,110OpenAlex ·
- 两年平均被引
- 4.25OpenAlex ·
- 自引率
- 7%LetPub ·
- Gold OA 文章占比
- 38.98%LetPub ·
发文规模
- 年文章数
- 167LetPub ·
逐年发文量 OpenAlex 统计 · 累计 9,323 篇 · 当年数据不完整
| 年份 | 发文量 | 其中 OA | 被引 |
|---|---|---|---|
| 2026 | 129 | 57 | 48 |
| 2025 | 183 | 100 | 592 |
| 2024 | 209 | 131 | 1,572 |
| 2023 | 184 | 106 | 2,275 |
| 2022 | 197 | 125 | 3,880 |
| 2021 | 146 | 77 | 3,017 |
不同来源的统计口径与观测时间不同，页面保留各来源原值；“出版商公布”为期刊官网自述数据。
审稿与录用
审稿周期与录用情况
- 平均审稿速度（社区反馈）
- 平均3.0个月来源Elsevier官网：平均9.6周LetPub ·
- 平均录用比例（社区反馈）
- 25%LetPub ·
- 投稿到首次决定
- 4 天出版商官网 ·
- 外审后首次决定
- 33 天出版商官网 ·
- 投稿到接收
- 81 天出版商官网 ·
- 接收到发表
- 2 天出版商官网 ·
社区反馈来自投稿者样本，置信度 0.5，不代表期刊承诺；“出版商公布”的时间节点定义以官网为准。
费用与开放获取
版面费与开放获取政策
混合开放获取LetPub
订阅期刊，作者可付费选择开放获取发表。
| 来源 | 文章处理费 | 费用减免 | 许可证 | 观测时间 |
|---|---|---|---|---|
| OpenAlex | USD 4,160 / EUR 3,890 / GBP 3,330 / JPY 515,960 | — | — | |
| 出版商官网 | USD 3,650 | — | — |
混合期刊的文章处理费仅在作者选择开放获取发表时收取；按订阅方式发表通常不收费。
费用以期刊官网为准；不同来源的观测时间可能不同，页面保留各来源原值，不做平均。
投稿要求
文章类型与投稿政策（官网）
接收的文章类型8 种，含篇幅限制
- commentariesReview articles and commentaries are published by invitation from the editor-in-chief, who will provide a check-list for manuscript preparation and submission.未说明篇幅
- commentaryResearch Articles should not exceed 3500 words. They should be divided into Abstract, Introduction, Materials and Methods, Results, Discussion and Acknowledgmen…未说明篇幅
- research articleResearch Articles should not exceed 3500 words. They should be divided into Abstract, Introduction, Materials and Methods, Results, Discussion and Acknowledgmen…正文 ≤ 3,500 词
- research articlesResearch Articles should not exceed 3500 words.未说明篇幅
- review articleResearch Articles should not exceed 3500 words. They should be divided into Abstract, Introduction, Materials and Methods, Results, Discussion and Acknowledgmen…未说明篇幅
- review articlesReview articles and commentaries are published by invitation from the editor-in-chief, who will provide a check-list for manuscript preparation and submission.未说明篇幅
- short communicationResearch Articles should not exceed 3500 words. They should be divided into Abstract, Introduction, Materials and Methods, Results, Discussion and Acknowledgmen…正文 ≤ 2,000 词
- short communicationsShort Communications should not exceed 2000 words and should not be divided into sections.未说明篇幅
官网政策摘录AI 使用、作者资格、利益冲突、许可与版权、开放获取、同行评审、预印本
- AI 使用 Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
原文 ↗出版商官网 ·- 作者资格 Group authorship
1 to 7 keywords 模型摘要
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
原文 ↗出版商官网 ·- 利益冲突 Declaration of competing interests
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
原文 ↗出版商官网 ·- 许可与版权 License options
Authors will be offered open access user license options which will determine how you, and third parties, can reuse your open access article. We advise that you review these options and any funding body license requirements before selecting a license option.
原文 ↗出版商官网 ·- 开放获取 Open access
We refer you to our open access information page to learn about open access options for this journal.
原文 ↗出版商官网 ·- 同行评审 Peer review
single anonymized review process 模型摘要
This journal follows a single anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Re…
原文 ↗出版商官网 ·- 预印本 Preprints
Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication. In support of Open Science, this journal offers its authors a free preprint posting service on SSRN, Elsevier’s preprint and early research …
原文 ↗出版商官网 ·
摘录来自期刊官网页面，仅保留原文片段；“模型摘要”由 Workers AI 生成并经原文校验，以官网为准。
基本信息
出版信息与官方入口
- 出版商
- Elsevier
- 出版国家或地区
- NETHERLANDS
- 出版语言
- English
- 出版周期
- Monthly
- 创刊年份
- 1981
- ISSN
- 0166-3542
- 电子版 ISSN
- 1872-9096
- 官方链接
- 期刊主页 ↗LetPub
- 投稿系统 ↗LetPub
- 专刊 / 特刊征稿 ↗出版商官网
常见问题
关于 ANTIVIRAL RESEARCH 的常见问题
ANTIVIRAL RESEARCH 是中科院几区期刊？
2025 年升级版分区表中，ANTIVIRAL RESEARCH 为医学 2区，小类 药学 / 病毒学 2 区。2026 年新锐版分区表中为医学 2区。不同版本与大小类分区不能混用。
ANTIVIRAL RESEARCH 的影响因子是多少？
LetPub 汇总的最新公布影响因子为 4.22，CiteScore 为 7.8，h-index 为 179。
ANTIVIRAL RESEARCH 的审稿周期多长？
投稿社区反馈的平均审稿速度为约 3 个月，平均录用比例反馈为“约25%”。社区反馈来自投稿者样本，不代表期刊承诺。
ANTIVIRAL RESEARCH 是开放获取期刊吗？版面费多少？
ANTIVIRAL RESEARCH 为混合开放获取。选择开放获取发表时APC 约 4,160 美元。
来源与更新
本页事实来自 LetPub、出版商官网、OpenAlex；每个数字旁标注来源与观测日期，冲突数据保留各来源原值。LetPub 原始详情页：查看 ↗（2026-08-25 归档）。最近更新：。